News from halozyme therapeutics, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 21, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Appoints Jean-Pierre Bizzari, M.D. To Board Of Directors

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Jean-Pierre Bizzari, M.D. to its Board of Directors. Dr. Bizzari...

Jan 12, 2015, 09:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Provides An Update On Anticipated Milestones For 2015 At The 33rd Annual J. P. Morgan Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update on anticipated 2015 corporate milestones. "Our progress in 2014 has set...

Jan 07, 2015, 08:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Provides Agenda Highlights For Analyst And Investor Meeting

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today will review the PEGPH20 development program and provide 2015 financial guidance during a meeting...

Jan 06, 2015, 16:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The 33rd Annual J.P. Morgan Healthcare Conference

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on...

Jan 05, 2015, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Appoints Athena Countouriotis, M.D. as Chief Medical Officer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Athena Countouriotis, M.D., as Chief Medical Officer where she...

Dec 30, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Therapeutics To Host Analyst And Investor Meeting

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced it will be hosting a meeting for analysts and investors in New York on Wednesday,...

Dec 19, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission, acting on the recommendation from the Committee for...

Dec 17, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize Subcutaneous Products Using ENHANZE™ Technology

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that it has entered into a worldwide Collaboration and License Agreement with Janssen...

Dec 12, 2014, 08:00 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at...

Dec 03, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday,...

Nov 25, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014...

Nov 10, 2014, 16:05 ET
Halozyme Therapeutics, Inc. Logo

Halozyme Reports Third Quarter 2014 Financial Results

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial...

Nov 05, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday,...

Nov 03, 2014, 16:15 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme to Host Third Quarter 2014 Financial Results Conference Call

Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10,...

Oct 20, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo.

Halozyme Receives FDA Approval For Additional Manufacturing Facilities For Hylenex® Recombinant

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has approved new contract...

Oct 09, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Podium Presentation On PEGPH20 At The New York Academy Of Sciences

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced an oral presentation on the pharmacology of PEGPH20 at the New York Academy of...

Oct 07, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Announces Issuance Of U.S. Patent For Companion Diagnostic For PEGPH20

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the issuance of U.S. Patent No. 8,846,034 claiming methods for selecting a...

Oct 03, 2014, 07:45 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme Receives Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer

Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for...

Sep 18, 2014, 09:00 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on...

Sep 03, 2014, 08:30 ET
Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.)

Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation

 Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation...